Table of Content

1 Report Overview
1.1 Ornithine-Transcarbamylase Deficiency Definition
1.2 Market by Type
1.2.1 Global Ornithine-Transcarbamylase Deficiency Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 DTX-301
1.2.3 SEL-313
1.2.4 SHP-641
1.2.5 PRX-OTC
1.2.6 Others
1.3 Market Segment by Application
1.3.1 Global Ornithine-Transcarbamylase Deficiency Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Ornithine-Transcarbamylase Deficiency Sales
2.1 Global Ornithine-Transcarbamylase Deficiency Revenue Estimates and Forecasts 2018-2034
2.2 Global Ornithine-Transcarbamylase Deficiency Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Ornithine-Transcarbamylase Deficiency Revenue by Region
2.3.1 Global Ornithine-Transcarbamylase Deficiency Revenue by Region (2018-2024)
2.3.2 Global Ornithine-Transcarbamylase Deficiency Revenue by Region (2024-2034)
2.4 Global Ornithine-Transcarbamylase Deficiency Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Ornithine-Transcarbamylase Deficiency Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Ornithine-Transcarbamylase Deficiency Sales Quantity by Region
2.6.1 Global Ornithine-Transcarbamylase Deficiency Sales Quantity by Region (2018-2024)
2.6.2 Global Ornithine-Transcarbamylase Deficiency Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Ornithine-Transcarbamylase Deficiency Sales Quantity by Manufacturers
3.1.1 Global Ornithine-Transcarbamylase Deficiency Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Ornithine-Transcarbamylase Deficiency Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Ornithine-Transcarbamylase Deficiency Sales in 2022
3.2 Global Ornithine-Transcarbamylase Deficiency Revenue by Manufacturers
3.2.1 Global Ornithine-Transcarbamylase Deficiency Revenue by Manufacturers (2018-2024)
3.2.2 Global Ornithine-Transcarbamylase Deficiency Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Ornithine-Transcarbamylase Deficiency Revenue in 2022
3.3 Global Ornithine-Transcarbamylase Deficiency Sales Price by Manufacturers
3.4 Global Key Players of Ornithine-Transcarbamylase Deficiency, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Ornithine-Transcarbamylase Deficiency Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Ornithine-Transcarbamylase Deficiency, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Ornithine-Transcarbamylase Deficiency, Product Offered and Application
3.8 Global Key Manufacturers of Ornithine-Transcarbamylase Deficiency, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Ornithine-Transcarbamylase Deficiency Sales Quantity by Type
4.1.1 Global Ornithine-Transcarbamylase Deficiency Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Ornithine-Transcarbamylase Deficiency Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Type (2018-2034)
4.2 Global Ornithine-Transcarbamylase Deficiency Revenue by Type
4.2.1 Global Ornithine-Transcarbamylase Deficiency Historical Revenue by Type (2018-2024)
4.2.2 Global Ornithine-Transcarbamylase Deficiency Forecasted Revenue by Type (2024-2034)
4.2.3 Global Ornithine-Transcarbamylase Deficiency Revenue Market Share by Type (2018-2034)
4.3 Global Ornithine-Transcarbamylase Deficiency Price by Type
4.3.1 Global Ornithine-Transcarbamylase Deficiency Price by Type (2018-2024)
4.3.2 Global Ornithine-Transcarbamylase Deficiency Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Ornithine-Transcarbamylase Deficiency Sales Quantity by Application
5.1.1 Global Ornithine-Transcarbamylase Deficiency Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Ornithine-Transcarbamylase Deficiency Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Application (2018-2034)
5.2 Global Ornithine-Transcarbamylase Deficiency Revenue by Application
5.2.1 Global Ornithine-Transcarbamylase Deficiency Historical Revenue by Application (2018-2024)
5.2.2 Global Ornithine-Transcarbamylase Deficiency Forecasted Revenue by Application (2024-2034)
5.2.3 Global Ornithine-Transcarbamylase Deficiency Revenue Market Share by Application (2018-2034)
5.3 Global Ornithine-Transcarbamylase Deficiency Price by Application
5.3.1 Global Ornithine-Transcarbamylase Deficiency Price by Application (2018-2024)
5.3.2 Global Ornithine-Transcarbamylase Deficiency Price Forecast by Application (2024-2034)
6 North America
6.1 North America Ornithine-Transcarbamylase Deficiency Sales by Company
6.1.1 North America Ornithine-Transcarbamylase Deficiency Revenue by Company (2018-2024)
6.1.2 North America Ornithine-Transcarbamylase Deficiency Sales Quantity by Company (2018-2024)
6.2 North America Ornithine-Transcarbamylase Deficiency Market Size by Type
6.2.1 North America Ornithine-Transcarbamylase Deficiency Sales Quantity by Type (2018-2034)
6.2.2 North America Ornithine-Transcarbamylase Deficiency Revenue by Type (2018-2034)
6.3 North America Ornithine-Transcarbamylase Deficiency Market Size by Application
6.3.1 North America Ornithine-Transcarbamylase Deficiency Sales Quantity by Application (2018-2034)
6.3.2 North America Ornithine-Transcarbamylase Deficiency Revenue by Application (2018-2034)
6.4 North America Ornithine-Transcarbamylase Deficiency Market Size by Country
6.4.1 North America Ornithine-Transcarbamylase Deficiency Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Ornithine-Transcarbamylase Deficiency Revenue by Country (2018-2034)
6.4.3 North America Ornithine-Transcarbamylase Deficiency Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Ornithine-Transcarbamylase Deficiency Sales by Company
7.1.1 Europe Ornithine-Transcarbamylase Deficiency Sales Quantity by Company (2018-2024)
7.1.2 Europe Ornithine-Transcarbamylase Deficiency Revenue by Company (2018-2024)
7.2 Europe Ornithine-Transcarbamylase Deficiency Market Size by Type
7.2.1 Europe Ornithine-Transcarbamylase Deficiency Sales Quantity by Type (2018-2034)
7.2.2 Europe Ornithine-Transcarbamylase Deficiency Revenue by Type (2018-2034)
7.3 Europe Ornithine-Transcarbamylase Deficiency Market Size by Application
7.3.1 Europe Ornithine-Transcarbamylase Deficiency Sales Quantity by Application (2018-2034)
7.3.2 Europe Ornithine-Transcarbamylase Deficiency Revenue by Application (2018-2034)
7.4 Europe Ornithine-Transcarbamylase Deficiency Market Size by Country
7.4.1 Europe Ornithine-Transcarbamylase Deficiency Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Ornithine-Transcarbamylase Deficiency Revenue by Country (2018-2034)
7.4.3 Europe Ornithine-Transcarbamylase Deficiency Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Ornithine-Transcarbamylase Deficiency Sales by Company
8.1.1 China Ornithine-Transcarbamylase Deficiency Sales Quantity by Company (2018-2024)
8.1.2 China Ornithine-Transcarbamylase Deficiency Revenue by Company (2018-2024)
8.2 China Ornithine-Transcarbamylase Deficiency Market Size by Type
8.2.1 China Ornithine-Transcarbamylase Deficiency Sales Quantity by Type (2018-2034)
8.2.2 China Ornithine-Transcarbamylase Deficiency Revenue by Type (2018-2034)
8.3 China Ornithine-Transcarbamylase Deficiency Market Size by Application
8.3.1 China Ornithine-Transcarbamylase Deficiency Sales Quantity by Application (2018-2034)
8.3.2 China Ornithine-Transcarbamylase Deficiency Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Ornithine-Transcarbamylase Deficiency Sales by Company
9.1.1 APAC Ornithine-Transcarbamylase Deficiency Sales Quantity by Company (2018-2024)
9.1.2 APAC Ornithine-Transcarbamylase Deficiency Revenue by Company (2018-2024)
9.2 APAC Ornithine-Transcarbamylase Deficiency Market Size by Type
9.2.1 APAC Ornithine-Transcarbamylase Deficiency Sales Quantity by Type (2018-2034)
9.2.2 APAC Ornithine-Transcarbamylase Deficiency Revenue by Type (2018-2034)
9.3 APAC Ornithine-Transcarbamylase Deficiency Market Size by Application
9.3.1 APAC Ornithine-Transcarbamylase Deficiency Sales Quantity by Application (2018-2034)
9.3.2 APAC Ornithine-Transcarbamylase Deficiency Revenue by Application (2018-2034)
9.4 APAC Ornithine-Transcarbamylase Deficiency Market Size by Region
9.4.1 APAC Ornithine-Transcarbamylase Deficiency Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Ornithine-Transcarbamylase Deficiency Revenue by Region (2018-2034)
9.4.3 APAC Ornithine-Transcarbamylase Deficiency Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Sales by Company
10.1.1 Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Market Size by Type
10.2.1 Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Market Size by Application
10.3.1 Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Market Size by Country
10.4.1 Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Lucane Pharma SA
11.1.1 Lucane Pharma SA Company Information
11.1.2 Lucane Pharma SA Overview
11.1.3 Lucane Pharma SA Ornithine-Transcarbamylase Deficiency Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Lucane Pharma SA Ornithine-Transcarbamylase Deficiency Products and Services
11.1.5 Lucane Pharma SA Ornithine-Transcarbamylase Deficiency SWOT Analysis
11.1.6 Lucane Pharma SA Recent Developments
11.2 PhaseRx Inc
11.2.1 PhaseRx Inc Company Information
11.2.2 PhaseRx Inc Overview
11.2.3 PhaseRx Inc Ornithine-Transcarbamylase Deficiency Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 PhaseRx Inc Ornithine-Transcarbamylase Deficiency Products and Services
11.2.5 PhaseRx Inc Ornithine-Transcarbamylase Deficiency SWOT Analysis
11.2.6 PhaseRx Inc Recent Developments
11.3 Promethera Biosciences SA
11.3.1 Promethera Biosciences SA Company Information
11.3.2 Promethera Biosciences SA Overview
11.3.3 Promethera Biosciences SA Ornithine-Transcarbamylase Deficiency Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Promethera Biosciences SA Ornithine-Transcarbamylase Deficiency Products and Services
11.3.5 Promethera Biosciences SA Ornithine-Transcarbamylase Deficiency SWOT Analysis
11.3.6 Promethera Biosciences SA Recent Developments
11.4 Selecta Biosciences Inc
11.4.1 Selecta Biosciences Inc Company Information
11.4.2 Selecta Biosciences Inc Overview
11.4.3 Selecta Biosciences Inc Ornithine-Transcarbamylase Deficiency Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Selecta Biosciences Inc Ornithine-Transcarbamylase Deficiency Products and Services
11.4.5 Selecta Biosciences Inc Ornithine-Transcarbamylase Deficiency SWOT Analysis
11.4.6 Selecta Biosciences Inc Recent Developments
11.5 Translate Bio Inc
11.5.1 Translate Bio Inc Company Information
11.5.2 Translate Bio Inc Overview
11.5.3 Translate Bio Inc Ornithine-Transcarbamylase Deficiency Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Translate Bio Inc Ornithine-Transcarbamylase Deficiency Products and Services
11.5.5 Translate Bio Inc Ornithine-Transcarbamylase Deficiency SWOT Analysis
11.5.6 Translate Bio Inc Recent Developments
11.6 Ultragenyx Pharmaceutical Inc
11.6.1 Ultragenyx Pharmaceutical Inc Company Information
11.6.2 Ultragenyx Pharmaceutical Inc Overview
11.6.3 Ultragenyx Pharmaceutical Inc Ornithine-Transcarbamylase Deficiency Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Ultragenyx Pharmaceutical Inc Ornithine-Transcarbamylase Deficiency Products and Services
11.6.5 Ultragenyx Pharmaceutical Inc Ornithine-Transcarbamylase Deficiency SWOT Analysis
11.6.6 Ultragenyx Pharmaceutical Inc Recent Developments
11.7 Unicyte AG
11.7.1 Unicyte AG Company Information
11.7.2 Unicyte AG Overview
11.7.3 Unicyte AG Ornithine-Transcarbamylase Deficiency Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Unicyte AG Ornithine-Transcarbamylase Deficiency Products and Services
11.7.5 Unicyte AG Ornithine-Transcarbamylase Deficiency SWOT Analysis
11.7.6 Unicyte AG Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Ornithine-Transcarbamylase Deficiency Value Chain Analysis
12.2 Ornithine-Transcarbamylase Deficiency Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Ornithine-Transcarbamylase Deficiency Production Mode & Process
12.4 Ornithine-Transcarbamylase Deficiency Sales and Marketing
12.4.1 Ornithine-Transcarbamylase Deficiency Sales Channels
12.4.2 Ornithine-Transcarbamylase Deficiency Distributors
12.5 Ornithine-Transcarbamylase Deficiency Customers
13 Market Dynamics
13.1 Ornithine-Transcarbamylase Deficiency Industry Trends
13.2 Ornithine-Transcarbamylase Deficiency Market Drivers
13.3 Ornithine-Transcarbamylase Deficiency Market Challenges
13.4 Ornithine-Transcarbamylase Deficiency Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Ornithine-Transcarbamylase Deficiency Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of DTX-301
Table 3. Major Manufacturers of SEL-313
Table 4. Major Manufacturers of SHP-641
Table 5. Major Manufacturers of PRX-OTC
Table 6. Major Manufacturers of Others
Table 7. Global Ornithine-Transcarbamylase Deficiency Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Ornithine-Transcarbamylase Deficiency Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 9. Global Ornithine-Transcarbamylase Deficiency Revenue by Region (2018-2024) & (US$ Million)
Table 10. Global Ornithine-Transcarbamylase Deficiency Revenue Market Share by Region (2018-2024)
Table 11. Global Ornithine-Transcarbamylase Deficiency Revenue by Region (2024-2034) & (US$ Million)
Table 12. Global Ornithine-Transcarbamylase Deficiency Revenue Market Share by Region (2024-2034)
Table 13. Global Ornithine-Transcarbamylase Deficiency Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Pcs)
Table 14. Global Ornithine-Transcarbamylase Deficiency Sales by Region (2018-2024) & (K Pcs)
Table 15. Global Ornithine-Transcarbamylase Deficiency Sales Market Share by Region (2018-2024)
Table 16. Global Ornithine-Transcarbamylase Deficiency Sales by Region (2024-2034) & (K Pcs)
Table 17. Global Ornithine-Transcarbamylase Deficiency Sales Market Share by Region (2024-2034)
Table 18. Global Ornithine-Transcarbamylase Deficiency Sales Quantity by Manufacturers (2018-2024) & (K Pcs)
Table 19. Global Ornithine-Transcarbamylase Deficiency Sales Quantity Share by Manufacturers (2018-2024)
Table 20. Global Ornithine-Transcarbamylase Deficiency Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 21. Global Ornithine-Transcarbamylase Deficiency Revenue Share by Manufacturers (2018-2024)
Table 22. Global Ornithine-Transcarbamylase Deficiency Price by Manufacturers 2018-2024 (USD/Pcs)
Table 23. Global Key Players of Ornithine-Transcarbamylase Deficiency, Industry Ranking, 2021 VS 2022
Table 24. Global Ornithine-Transcarbamylase Deficiency Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 25. Global Ornithine-Transcarbamylase Deficiency by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ornithine-Transcarbamylase Deficiency as of 2022)
Table 26. Global Key Manufacturers of Ornithine-Transcarbamylase Deficiency, Manufacturing Base Distribution and Headquarters
Table 27. Global Key Manufacturers of Ornithine-Transcarbamylase Deficiency, Product Offered and Application
Table 28. Global Key Manufacturers of Ornithine-Transcarbamylase Deficiency, Date of Enter into This Industry
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Ornithine-Transcarbamylase Deficiency Sales Quantity by Type (2018-2024) & (K Pcs)
Table 31. Global Ornithine-Transcarbamylase Deficiency Sales Quantity by Type (2024-2034) & (K Pcs)
Table 32. Global Ornithine-Transcarbamylase Deficiency Sales Quantity Share by Type (2018-2024)
Table 33. Global Ornithine-Transcarbamylase Deficiency Sales Quantity Share by Type (2024-2034)
Table 34. Global Ornithine-Transcarbamylase Deficiency Revenue by Type (2018-2024) & (US$ Million)
Table 35. Global Ornithine-Transcarbamylase Deficiency Revenue by Type (2024-2034) & (US$ Million)
Table 36. Global Ornithine-Transcarbamylase Deficiency Revenue Share by Type (2018-2024)
Table 37. Global Ornithine-Transcarbamylase Deficiency Revenue Share by Type (2024-2034)
Table 38. Ornithine-Transcarbamylase Deficiency Price by Type (2018-2024) & (USD/Pcs)
Table 39. Global Ornithine-Transcarbamylase Deficiency Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 40. Global Ornithine-Transcarbamylase Deficiency Sales Quantity by Application (2018-2024) & (K Pcs)
Table 41. Global Ornithine-Transcarbamylase Deficiency Sales Quantity by Application (2024-2034) & (K Pcs)
Table 42. Global Ornithine-Transcarbamylase Deficiency Sales Quantity Share by Application (2018-2024)
Table 43. Global Ornithine-Transcarbamylase Deficiency Sales Quantity Share by Application (2024-2034)
Table 44. Global Ornithine-Transcarbamylase Deficiency Revenue by Application (2018-2024) & (US$ Million)
Table 45. Global Ornithine-Transcarbamylase Deficiency Revenue by Application (2024-2034) & (US$ Million)
Table 46. Global Ornithine-Transcarbamylase Deficiency Revenue Share by Application (2018-2024)
Table 47. Global Ornithine-Transcarbamylase Deficiency Revenue Share by Application (2024-2034)
Table 48. Ornithine-Transcarbamylase Deficiency Price by Application (2018-2024) & (USD/Pcs)
Table 49. Global Ornithine-Transcarbamylase Deficiency Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 50. North America Ornithine-Transcarbamylase Deficiency Revenue by Company (2018-2024) & (US$ Million)
Table 51. North America Ornithine-Transcarbamylase Deficiency Sales Quantity by Company (2018-2024) & (K Pcs)
Table 52. North America Ornithine-Transcarbamylase Deficiency Sales Quantity by Type (2018-2024) & (K Pcs)
Table 53. North America Ornithine-Transcarbamylase Deficiency Sales Quantity by Type (2024-2034) & (K Pcs)
Table 54. North America Ornithine-Transcarbamylase Deficiency Revenue by Type (2018-2024) & (US$ Million)
Table 55. North America Ornithine-Transcarbamylase Deficiency Revenue by Type (2024-2034) & (US$ Million)
Table 56. North America Ornithine-Transcarbamylase Deficiency Sales Quantity by Application (2018-2024) & (K Pcs)
Table 57. North America Ornithine-Transcarbamylase Deficiency Sales Quantity by Application (2024-2034) & (K Pcs)
Table 58. North America Ornithine-Transcarbamylase Deficiency Revenue by Application (2018-2024) & (US$ Million)
Table 59. North America Ornithine-Transcarbamylase Deficiency Revenue by Application (2024-2034) & (US$ Million)
Table 60. North America Ornithine-Transcarbamylase Deficiency Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 61. North America Ornithine-Transcarbamylase Deficiency Revenue by Country (2018-2024) & (US$ Million)
Table 62. North America Ornithine-Transcarbamylase Deficiency Revenue by Country (2024-2034) & (US$ Million)
Table 63. North America Ornithine-Transcarbamylase Deficiency Sales Quantity by Country (2018-2024) & (K Pcs)
Table 64. North America Ornithine-Transcarbamylase Deficiency Sales Quantity by Country (2024-2034) & (K Pcs)
Table 65. Europe Ornithine-Transcarbamylase Deficiency Sales Quantity by Company (2018-2024) & (K Pcs)
Table 66. Europe Ornithine-Transcarbamylase Deficiency Revenue by Company (2018-2024) & (US$ Million)
Table 67. Europe Ornithine-Transcarbamylase Deficiency Sales Quantity by Type (2018-2024) & (K Pcs)
Table 68. Europe Ornithine-Transcarbamylase Deficiency Sales Quantity by Type (2024-2034) & (K Pcs)
Table 69. Europe Ornithine-Transcarbamylase Deficiency Revenue by Type (2018-2024) & (US$ Million)
Table 70. Europe Ornithine-Transcarbamylase Deficiency Revenue by Type (2024-2034) & (US$ Million)
Table 71. Europe Ornithine-Transcarbamylase Deficiency Sales Quantity by Application (2018-2024) & (K Pcs)
Table 72. Europe Ornithine-Transcarbamylase Deficiency Sales Quantity by Application (2024-2034) & (K Pcs)
Table 73. Europe Ornithine-Transcarbamylase Deficiency Revenue by Application (2018-2024) & (US$ Million)
Table 74. Europe Ornithine-Transcarbamylase Deficiency Revenue by Application (2024-2034) & (US$ Million)
Table 75. Europe Ornithine-Transcarbamylase Deficiency Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 76. Europe Ornithine-Transcarbamylase Deficiency Revenue by Country (2018-2024) & (US$ Million)
Table 77. Europe Ornithine-Transcarbamylase Deficiency Revenue by Country (2024-2034) & (US$ Million)
Table 78. Europe Ornithine-Transcarbamylase Deficiency Sales Quantity by Country (2018-2024) & (K Pcs)
Table 79. Europe Ornithine-Transcarbamylase Deficiency Sales Quantity by Country (2024-2034) & (K Pcs)
Table 80. China Ornithine-Transcarbamylase Deficiency Sales Quantity by Company (2018-2024) & (K Pcs)
Table 81. China Ornithine-Transcarbamylase Deficiency Revenue by Company (2018-2024) & (US$ Million)
Table 82. China Ornithine-Transcarbamylase Deficiency Sales Quantity by Type (2018-2024) & (K Pcs)
Table 83. China Ornithine-Transcarbamylase Deficiency Sales Quantity by Type (2024-2034) & (K Pcs)
Table 84. China Ornithine-Transcarbamylase Deficiency Revenue by Type (2018-2024) & (US$ Million)
Table 85. China Ornithine-Transcarbamylase Deficiency Revenue by Type (2024-2034) & (US$ Million)
Table 86. China Ornithine-Transcarbamylase Deficiency Sales Quantity by Application (2018-2024) & (K Pcs)
Table 87. China Ornithine-Transcarbamylase Deficiency Sales Quantity by Application (2024-2034) & (K Pcs)
Table 88. China Ornithine-Transcarbamylase Deficiency Revenue by Application (2018-2024) & (US$ Million)
Table 89. China Ornithine-Transcarbamylase Deficiency Revenue by Application (2024-2034) & (US$ Million)
Table 90. APAC Ornithine-Transcarbamylase Deficiency Sales Quantity by Company (2018-2024) & (K Pcs)
Table 91. APAC Ornithine-Transcarbamylase Deficiency Revenue by Company (2018-2024) & (US$ Million)
Table 92. APAC Ornithine-Transcarbamylase Deficiency Sales Quantity by Type (2018-2024) & (K Pcs)
Table 93. APAC Ornithine-Transcarbamylase Deficiency Sales Quantity by Type (2024-2034) & (K Pcs)
Table 94. APAC Ornithine-Transcarbamylase Deficiency Revenue by Type (2018-2024) & (US$ Million)
Table 95. APAC Ornithine-Transcarbamylase Deficiency Revenue by Type (2024-2034) & (US$ Million)
Table 96. APAC Ornithine-Transcarbamylase Deficiency Sales Quantity by Application (2018-2024) & (K Pcs)
Table 97. APAC Ornithine-Transcarbamylase Deficiency Sales Quantity by Application (2024-2034) & (K Pcs)
Table 98. APAC Ornithine-Transcarbamylase Deficiency Revenue by Application (2018-2024) & (US$ Million)
Table 99. APAC Ornithine-Transcarbamylase Deficiency Revenue by Application (2024-2034) & (US$ Million)
Table 100. APAC Ornithine-Transcarbamylase Deficiency Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 101. APAC Ornithine-Transcarbamylase Deficiency Revenue by Region (2018-2024) & (US$ Million)
Table 102. APAC Ornithine-Transcarbamylase Deficiency Revenue by Region (2024-2034) & (US$ Million)
Table 103. APAC Ornithine-Transcarbamylase Deficiency Sales Quantity by Region (2018-2024) & (K Pcs)
Table 104. APAC Ornithine-Transcarbamylase Deficiency Sales Quantity by Region (2024-2034) & (K Pcs)
Table 105. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Sales Quantity by Company (2018-2024) & (K Pcs)
Table 106. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Revenue by Company (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Sales Quantity by Type (2018-2024) & (K Pcs)
Table 108. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Sales Quantity by Type (2024-2034) & (K Pcs)
Table 109. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Revenue by Type (2018-2024) & (US$ Million)
Table 110. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Revenue by Type (2024-2034) & (US$ Million)
Table 111. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Sales Quantity by Application (2018-2024) & (K Pcs)
Table 112. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Sales Quantity by Application (2024-2034) & (K Pcs)
Table 113. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Revenue by Application (2018-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Revenue by Application (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 116. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Revenue by Country (2018-2024) & (US$ Million)
Table 117. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Revenue by Country (2024-2034) & (US$ Million)
Table 118. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Sales Quantity by Country (2018-2024) & (K Pcs)
Table 119. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Sales Quantity by Country (2024-2034) & (K Pcs)
Table 120. Lucane Pharma SA Company Information
Table 121. Lucane Pharma SA Description and Overview
Table 122. Lucane Pharma SA Ornithine-Transcarbamylase Deficiency Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 123. Lucane Pharma SA Ornithine-Transcarbamylase Deficiency Product and Services
Table 124. Lucane Pharma SA Ornithine-Transcarbamylase Deficiency SWOT Analysis
Table 125. Lucane Pharma SA Recent Developments
Table 126. PhaseRx Inc Company Information
Table 127. PhaseRx Inc Description and Overview
Table 128. PhaseRx Inc Ornithine-Transcarbamylase Deficiency Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 129. PhaseRx Inc Ornithine-Transcarbamylase Deficiency Product and Services
Table 130. PhaseRx Inc Ornithine-Transcarbamylase Deficiency SWOT Analysis
Table 131. PhaseRx Inc Recent Developments
Table 132. Promethera Biosciences SA Company Information
Table 133. Promethera Biosciences SA Description and Overview
Table 134. Promethera Biosciences SA Ornithine-Transcarbamylase Deficiency Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 135. Promethera Biosciences SA Ornithine-Transcarbamylase Deficiency Product and Services
Table 136. Promethera Biosciences SA Ornithine-Transcarbamylase Deficiency SWOT Analysis
Table 137. Promethera Biosciences SA Recent Developments
Table 138. Selecta Biosciences Inc Company Information
Table 139. Selecta Biosciences Inc Description and Overview
Table 140. Selecta Biosciences Inc Ornithine-Transcarbamylase Deficiency Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 141. Selecta Biosciences Inc Ornithine-Transcarbamylase Deficiency Product and Services
Table 142. Selecta Biosciences Inc Ornithine-Transcarbamylase Deficiency SWOT Analysis
Table 143. Selecta Biosciences Inc Recent Developments
Table 144. Translate Bio Inc Company Information
Table 145. Translate Bio Inc Description and Overview
Table 146. Translate Bio Inc Ornithine-Transcarbamylase Deficiency Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 147. Translate Bio Inc Ornithine-Transcarbamylase Deficiency Product and Services
Table 148. Translate Bio Inc Ornithine-Transcarbamylase Deficiency SWOT Analysis
Table 149. Translate Bio Inc Recent Developments
Table 150. Ultragenyx Pharmaceutical Inc Company Information
Table 151. Ultragenyx Pharmaceutical Inc Description and Overview
Table 152. Ultragenyx Pharmaceutical Inc Ornithine-Transcarbamylase Deficiency Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 153. Ultragenyx Pharmaceutical Inc Ornithine-Transcarbamylase Deficiency Product and Services
Table 154. Ultragenyx Pharmaceutical Inc Ornithine-Transcarbamylase Deficiency SWOT Analysis
Table 155. Ultragenyx Pharmaceutical Inc Recent Developments
Table 156. Unicyte AG Company Information
Table 157. Unicyte AG Description and Overview
Table 158. Unicyte AG Ornithine-Transcarbamylase Deficiency Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 159. Unicyte AG Ornithine-Transcarbamylase Deficiency Product and Services
Table 160. Unicyte AG Ornithine-Transcarbamylase Deficiency SWOT Analysis
Table 161. Unicyte AG Recent Developments
Table 162. Key Raw Materials Lists
Table 163. Raw Materials Key Suppliers Lists
Table 164. Ornithine-Transcarbamylase Deficiency Distributors List
Table 165. Ornithine-Transcarbamylase Deficiency Customers List
Table 166. Ornithine-Transcarbamylase Deficiency Market Trends
Table 167. Ornithine-Transcarbamylase Deficiency Market Drivers
Table 168. Ornithine-Transcarbamylase Deficiency Market Challenges
Table 169. Ornithine-Transcarbamylase Deficiency Market Restraints
Table 170. Research Programs/Design for This Report
Table 171. Key Data Information from Secondary Sources
Table 172. Key Data Information from Primary Sources
List of Figures
Figure 1. Ornithine-Transcarbamylase Deficiency Product Picture
Figure 2. Global Ornithine-Transcarbamylase Deficiency Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Ornithine-Transcarbamylase Deficiency Market Share by Type in 2022 & 2034
Figure 4. DTX-301 Product Picture
Figure 5. SEL-313 Product Picture
Figure 6. SHP-641 Product Picture
Figure 7. PRX-OTC Product Picture
Figure 8. Others Product Picture
Figure 9. Global Ornithine-Transcarbamylase Deficiency Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 10. Global Ornithine-Transcarbamylase Deficiency Market Share by Application in 2022 & 2034
Figure 11. Hospital
Figure 12. Clinic
Figure 13. Others
Figure 14. Ornithine-Transcarbamylase Deficiency Report Years Considered
Figure 15. Global Ornithine-Transcarbamylase Deficiency Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 16. Global Ornithine-Transcarbamylase Deficiency Revenue 2018-2034 (US$ Million)
Figure 17. Global Ornithine-Transcarbamylase Deficiency Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 18. Global Ornithine-Transcarbamylase Deficiency Sales Quantity 2018-2034 (K Pcs)
Figure 19. Global Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Region (2018-2024)
Figure 20. Global Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Region (2024-2034)
Figure 21. North America Ornithine-Transcarbamylase Deficiency Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 22. North America Ornithine-Transcarbamylase Deficiency Revenue YoY (2018-2034) & (US$ Million)
Figure 23. Europe Ornithine-Transcarbamylase Deficiency Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 24. Europe Ornithine-Transcarbamylase Deficiency Revenue YoY (2018-2034) & (US$ Million)
Figure 25. China Ornithine-Transcarbamylase Deficiency Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 26. China Ornithine-Transcarbamylase Deficiency Revenue YoY (2018-2034) & (US$ Million)
Figure 27. APAC Ornithine-Transcarbamylase Deficiency Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 28. APAC Ornithine-Transcarbamylase Deficiency Revenue YoY (2018-2034) & (US$ Million)
Figure 29. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 30. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Revenue YoY (2018-2034) & (US$ Million)
Figure 31. The Top 10 and Top 5 Players Market Share by Ornithine-Transcarbamylase Deficiency Sales Quantity in 2022
Figure 32. The Top 10 and Top 5 Players Market Share by Ornithine-Transcarbamylase Deficiency Revenue in 2022
Figure 33. Ornithine-Transcarbamylase Deficiency Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 34. Global Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Type (2018-2034)
Figure 35. Global Ornithine-Transcarbamylase Deficiency Revenue Market Share by Type (2018-2034)
Figure 36. Global Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Application (2018-2034)
Figure 37. Global Ornithine-Transcarbamylase Deficiency Revenue Market Share by Application (2018-2034)
Figure 38. North America Ornithine-Transcarbamylase Deficiency Revenue Market Share by Company in 2022
Figure 39. North America Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Company in 2022
Figure 40. North America Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Type (2018-2034)
Figure 41. North America Ornithine-Transcarbamylase Deficiency Revenue Market Share by Type (2018-2034)
Figure 42. North America Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Application (2018-2034)
Figure 43. North America Ornithine-Transcarbamylase Deficiency Revenue Market Share by Application (2018-2034)
Figure 44. North America Ornithine-Transcarbamylase Deficiency Revenue Share by Country (2018-2034)
Figure 45. North America Ornithine-Transcarbamylase Deficiency Sales Quantity Share by Country (2018-2034)
Figure 46. U.S. Ornithine-Transcarbamylase Deficiency Revenue (2018-2034) & (US$ Million)
Figure 47. Canada Ornithine-Transcarbamylase Deficiency Revenue (2018-2034) & (US$ Million)
Figure 48. Europe Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Company in 2022
Figure 49. Europe Ornithine-Transcarbamylase Deficiency Revenue Market Share by Company in 2022
Figure 50. Europe Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Type (2018-2034)
Figure 51. Europe Ornithine-Transcarbamylase Deficiency Revenue Market Share by Type (2018-2034)
Figure 52. Europe Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Application (2018-2034)
Figure 53. Europe Ornithine-Transcarbamylase Deficiency Revenue Market Share by Application (2018-2034)
Figure 54. Europe Ornithine-Transcarbamylase Deficiency Revenue Share by Country (2018-2034)
Figure 55. Europe Ornithine-Transcarbamylase Deficiency Sales Quantity Share by Country (2018-2034)
Figure 56. Germany Ornithine-Transcarbamylase Deficiency Revenue (2018-2034) & (US$ Million)
Figure 57. France Ornithine-Transcarbamylase Deficiency Revenue (2018-2034) & (US$ Million)
Figure 58. U.K. Ornithine-Transcarbamylase Deficiency Revenue (2018-2034) & (US$ Million)
Figure 59. Italy Ornithine-Transcarbamylase Deficiency Revenue (2018-2034) & (US$ Million)
Figure 60. Russia Ornithine-Transcarbamylase Deficiency Revenue (2018-2034) & (US$ Million)
Figure 61. China Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Company in 2022
Figure 62. China Ornithine-Transcarbamylase Deficiency Revenue Market Share by Company in 2022
Figure 63. China Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Type (2018-2034)
Figure 64. China Ornithine-Transcarbamylase Deficiency Revenue Market Share by Type (2018-2034)
Figure 65. China Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Application (2018-2034)
Figure 66. China Ornithine-Transcarbamylase Deficiency Revenue Market Share by Application (2018-2034)
Figure 67. APAC Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Company in 2022
Figure 68. APAC Ornithine-Transcarbamylase Deficiency Revenue Market Share by Company in 2022
Figure 69. APAC Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Type (2018-2034)
Figure 70. APAC Ornithine-Transcarbamylase Deficiency Revenue Market Share by Type (2018-2034)
Figure 71. APAC Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Application (2018-2034)
Figure 72. APAC Ornithine-Transcarbamylase Deficiency Revenue Market Share by Application (2018-2034)
Figure 73. APAC Ornithine-Transcarbamylase Deficiency Revenue Share by Region (2018-2034)
Figure 74. APAC Ornithine-Transcarbamylase Deficiency Sales Quantity Share by Region (2018-2034)
Figure 75. Japan Ornithine-Transcarbamylase Deficiency Revenue (2018-2034) & (US$ Million)
Figure 76. South Korea Ornithine-Transcarbamylase Deficiency Revenue (2018-2034) & (US$ Million)
Figure 77. China Taiwan Ornithine-Transcarbamylase Deficiency Revenue (2018-2034) & (US$ Million)
Figure 78. Southeast Asia Ornithine-Transcarbamylase Deficiency Revenue (2018-2034) & (US$ Million)
Figure 79. India Ornithine-Transcarbamylase Deficiency Revenue (2018-2034) & (US$ Million)
Figure 80. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Company in 2022
Figure 81. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Revenue Market Share by Company in 2022
Figure 82. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Revenue Market Share by Type (2018-2034)
Figure 84. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Sales Quantity Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Revenue Market Share by Application (2018-2034)
Figure 86. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Sales Quantity Share by Country (2018-2034)
Figure 87. Middle East, Africa and Latin America Ornithine-Transcarbamylase Deficiency Revenue Share by Country (2018-2034)
Figure 88. Brazil Ornithine-Transcarbamylase Deficiency Revenue (2018-2034) & (US$ Million)
Figure 89. Mexico Ornithine-Transcarbamylase Deficiency Revenue (2018-2034) & (US$ Million)
Figure 90. Turkey Ornithine-Transcarbamylase Deficiency Revenue (2018-2034) & (US$ Million)
Figure 91. Israel Ornithine-Transcarbamylase Deficiency Revenue (2018-2034) & (US$ Million)
Figure 92. GCC Countries Ornithine-Transcarbamylase Deficiency Revenue (2018-2034) & (US$ Million)
Figure 93. Ornithine-Transcarbamylase Deficiency Value Chain
Figure 94. Ornithine-Transcarbamylase Deficiency Production Process
Figure 95. Channels of Distribution (Direct Vs Distribution)
Figure 96. Distributors Profiles
Figure 97. Bottom-up and Top-down Approaches for This Report
Figure 98. Data Triangulation
Figure 99. Key Executives Interviewed